X4 PHARMACEUTICALS, INC Income (Loss) from Continuing Operations before Income Taxes, Domestic
X4 PHARMACEUTICALS, INC (XFOR) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$79.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-17
- X4 PHARMACEUTICALS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$79.41M.
- X4 PHARMACEUTICALS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$38.85M.
- X4 PHARMACEUTICALS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$102.13M.
- X4 PHARMACEUTICALS, INC income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$94.74M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$79.41M 10-K · filed 2026-03-17 | |
| 2024-12-31 | -$38.85M 10-K · filed 2026-03-17 | |
| 2023-12-31 | -$102.13M 10-K · filed 2026-03-17 | |
| 2022-12-31 | -$94.74M 10-K · filed 2025-03-26 | |
| 2021-12-31 | -$89.86M 10-K · filed 2024-03-21 | |
| 2020-12-31 | -$62.54M 10-K · filed 2023-03-21 | |
| 2019-12-31 | -$52.31M 10-K · filed 2022-03-17 | |
| 2018-12-31 | -$33.28M 10-K · filed 2021-03-19 | -$32.02M 10-K · filed 2019-03-11 |
| 2017-12-31 | -$21.99M 10-K · filed 2020-03-12 | -$24.62M 10-K · filed 2019-03-11 |
| 2016-12-31 | -$12.97M 10-K · filed 2019-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |